Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Several other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Wednesday, August 14th. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.50 on Tuesday. The company has a market cap of $81.46 million, a price-to-earnings ratio of -2.54 and a beta of 0.50. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. The firm has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $0.97. Cytosorbents has a one year low of $0.70 and a one year high of $2.15.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. During the same quarter in the prior year, the firm earned ($0.14) EPS. Research analysts predict that Cytosorbents will post -0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently modified their holdings of CTSO. Neuberger Berman Group LLC increased its position in shares of Cytosorbents by 19.9% during the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after buying an additional 299,103 shares during the period. Avenir Corp increased its position in shares of Cytosorbents by 12.3% during the fourth quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock worth $3,387,000 after buying an additional 334,005 shares during the period. Key Client Fiduciary Advisors LLC increased its position in shares of Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares during the period. CM Management LLC increased its position in shares of Cytosorbents by 98.8% during the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after buying an additional 410,000 shares during the period. Finally, Sargent Investment Group LLC increased its position in shares of Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.